Intercept Stock Price Skyrockets On Continuing Stream Of Good Data For OCA Candidates

Early stop due to efficacy of NIH Phase II trial in non-alcoholic steatohepatitis could mean quick pathway to approval for compound in this unmet medical need. A growing liver disease, Intercept believes NASH is an under-recognized opportunity, which could outstrip HCV and cirrhosis as a cause of liver transplantation.